Skip to content
  • About the Association
    • Generic Quality
    • About AAM
    • Our Team
    • Our Members
    • Generic Medicines
    • Biosimilars Council
    • Meet Our Board
    • Community Commitment
    • Careers
    • Contact Us
  • About the Association
    • Generic Quality
    • About AAM
    • Our Team
    • Our Members
    • Generic Medicines
    • Biosimilars Council
    • Meet Our Board
    • Community Commitment
    • Careers
    • Contact Us
  • Resources
    • 2024 Saving Report
    • 2025 Advocacy Priorities
    • 2025 First Generics White Paper
    • Drug Shortages White Paper
    • Biosimilars Patient Resource Center
    • Biosimilar Research & Studies
    • Blog
    • Founders Blogs
    • Amicus Briefs
    • Patient Stories
  • Resources
    • 2024 Saving Report
    • 2025 Advocacy Priorities
    • 2025 First Generics White Paper
    • Drug Shortages White Paper
    • Biosimilars Patient Resource Center
    • Biosimilar Research & Studies
    • Blog
    • Founders Blogs
    • Amicus Briefs
    • Patient Stories
  • Advocacy
    • Federal Advocacy
    • Biosimilars
    • GDUFA/BsUFA User Fees
    • Inflation Reduction Act
    • Intellectual Property & Patent Reform
    • Medicaid Generics Penalty
    • State Advocacy
    • Tariffs & Trade
  • Events
    • GRx+Biosims 2025
    • Access! 2026
  • Press Releases
  • JOIN
  • Advocacy
    • Federal Advocacy
    • Biosimilars
    • GDUFA/BsUFA User Fees
    • Inflation Reduction Act
    • Intellectual Property & Patent Reform
    • Medicaid Generics Penalty
    • State Advocacy
    • Tariffs & Trade
  • Events
    • GRx+Biosims 2025
    • Access! 2026
  • Press Releases
  • JOIN
Search Icon
SideMenu
Home
Blog

Biosimilars Council Press Releases

Blog

  • Blog
  • July 14, 2025
  • AAM

Long-Term Effects of Medicare Price Negotiations on Drug Competition

  • Blog
  • June 3, 2025
  • AAM

$423B Savings from Patent Settlements Since Actavis Ruling

  • Blog
  • June 3, 2025
  • AAM

Patent Settlements Are Necessary To Help Combat Patent Thickets

  • Blog
  • February 10, 2025
  • AAM

The IRA Hurts Generic and Biosimilar Medication Competition

  • Blog
  • February 6, 2025
  • AAM

Access! 2025 Recap: A Call to Action for the Future of Generics and Biosimilars

  • Blog
  • February 5, 2025
  • AAM

Your All ACCESS! Pass

  • Blog
  • January 27, 2025
  • AAM

Redesigned Medicare Drug Program Still Allows PBMs to Deny Patients Access to Lower-Cost Generics & Biosimilars

  • Blog
  • December 11, 2024
  • AAM

Congress Should Pass Legislation to End the Shenanigans That Allow Brand-Name Drug Manufacturers to Delay Generic Competition and Charge Higher Prices for Longer Periods

  • Blog
  • November 8, 2024
  • AAM

GRx+Biosims 2024 Conference Recap

  • Blog
  • September 10, 2024
  • AAM

Want to Save Patients Money on Medicine? No Need to Reinvent the Wheel

  • Blog
  • June 25, 2024
  • AAM

Senate Finance Committee Bill Addressing Drug Shortages Would Provide Long Overdue Relief from Penalties Hurting Generic Drug Market

  • Blog
  • April 16, 2024
  • AAM

Seniors Pay More for Generic Medicines Every Year While Prices Continue to Fall. Why?

Load More
Association for Accessible Medicines
601 New Jersey Ave NW, Suite 850
Washington DC 20001
  • 202.249.7100
  • info@accessiblemeds.org
JOIN

Advocacy

  • Federal Advocacy
  • Biosimilars
  • GDUFA/BsUFA User Fees
  • Intellectual Property & Patent Reform
  • Inflation Reduction Act
  • Medicaid Generics Penalty
  • State Advocacy
  • Tariffs & Trade
  • Press Releases
  • Stay Informed

About Us

  • Generic Quality
  • Our Team
  • Our Members
  • Generic Medicines
  • Biosimilars Council
  • Meet Our Board
  • Community Commitment
  • Careers
  • Contact Us

Events

  • GRx+Biosims 2025
  • Access! 2026

Resources

  • 2024 Savings Report
  • Drug Shortages
White Paper
  • Biosimilars Patient
Resource Center
  • Biosimilars Research &
Studies
  • Blog
  • Founders Blogs
  • Amicus Briefs
  • Patient Stories

Sign-up for Update

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Subscribe

© 2025 Association for Accessible Medicines (AAM), All Rights Reserved
Privacy Policy  |  Terms of Use  |  Contact

Stay Connected

For the latest updates, follow us on social media.

Facebook-f X-twitter Linkedin-in Youtube Instagram
  • Resources
    • 2024 Saving Report
    • 2025 Advocacy Priorities
    • 2025 First Generics White Paper
    • Drug Shortages White Paper
    • Biosimilars Patient Resource Center
    • Biosimilar Research & Studies
    • Blog
    • Founders Blogs
    • Amicus Briefs
    • Patient Stories
  • About the Association
    • Generic Quality
    • About AAM
    • Our Team
    • Our Members
    • Generic Medicines
    • Biosimilars Council
    • Meet Our Board
    • Community Commitment
    • Careers
    • Contact Us
  • Advocacy
    • Federal Advocacy
    • Biosimilars
    • GDUFA/BsUFA User Fees
    • Inflation Reduction Act
    • Intellectual Property & Patent Reform
    • Medicaid Generics Penalty
    • State Advocacy
    • Tariffs & Trade
  • Events
    • GRx+Biosims 2025
    • Access! 2026
  • Press Releases
  • JOIN
  • About the Association
    • Generic Quality
    • About AAM
    • Our Team
    • Our Members
    • Generic Medicines
    • Biosimilars Council
    • Meet Our Board
    • Community Commitment
    • Careers
    • Contact Us
  • Resources
    • 2024 Saving Report
    • 2025 Advocacy Priorities
    • 2025 First Generics White Paper
    • Drug Shortages White Paper
    • Biosimilars Patient Resource Center
    • Biosimilar Research & Studies
    • Blog
    • Founders Blogs
    • Amicus Briefs
    • Patient Stories
  • Advocacy
    • Federal Advocacy
    • Biosimilars
    • GDUFA/BsUFA User Fees
    • Inflation Reduction Act
    • Intellectual Property & Patent Reform
    • Medicaid Generics Penalty
    • State Advocacy
    • Tariffs & Trade
  • Events
    • GRx+Biosims 2025
    • Access! 2026
  • Press Releases
  • JOIN